Novartis AG (NYSE:NVS) is one of the top gene therapy stocks to buy according to hedge funds. Novartis AG (NYSE:NVS) ...

Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

Novartis AG will sell its entire 70.68% stake in Novartis India to a ChrysCapital-led consortium for Rs 1,446 crore, ...

President Donald Trump said his tariffs spurred Novartis AG to expand its US manufacturing footprint, following a meeting with the Swiss drugmaker’s chief executive Vas Narasimhan at the White House ...

Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. (“Avidity”). With the completion of the acquisition, ...

In the real-world, Pluvicto showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal-world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead ...

Loomis Sayles, an investment management company, released its “Global Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund ...

Swiss pharmaceutical Novartis AG (NYSE: NVS) reported fourth-quarter 2025 results on Wednesday. The company's net sales rose 1% year over year to $13.34 billion, missing Wall Street's consensus ...

CSU affects nearly 4 million people in Europe, with over 50% of patients remaining symptomatic despite H1-antihistamines2-4 ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Defendants MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., and Novadoz Pharmaceuticals LLC moved to stay the preliminary injunction granted to plaintiffs Novartis AG and Novartis ...